Will Argentina Be The Next Medtech Clinical Trial Destination In Latin America?
By Julio G. Martinez-Clark, CEO, bioaccess
With a population surpassing 44 million, Argentina presents a compelling proposition for medtech clinical trials, bolstered by its robust healthcare system, modern facilities, and a cadre of experienced medical professionals. The country's position in the global arena is further underscored by its rank of 20th out of 46 in the 2020–2021 Medical Tourism Index, highlighting its healthcare system's high doctor-patient ratio, top-notch medical facilities, and substantial healthcare investments. This underlines Argentina's emerging prominence in the medtech sector, particularly in cosmetic and reconstructive surgeries, regenerative medicine, cardiology, and other medical procedures, offering competitive expertise and pricing advantages.
As stakeholders in the Argentina clinical research landscape, including contract research organizations (CROs), navigate the expeditious clinical trial approval timeline, positive developments in the local clinical research industry continue to unfold. These advancements, alongside a robust clinical trial hospital infrastructure, underscore the nation's potential ascendancy as the next major hub for medtech clinical trial activity, poised to attract increased foreign sponsorship and partnership. From 2018 to 2022, Argentina's clinical trial industry's market size increased by 126.6%, from $7.2 million to $88.9 million. This article will explore Argentina's medical device clinical trial landscape. It will explore why this South American country is now one of Latin America's top clinical trial destinations.
